Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New drug combo aims to make bone marrow transplants safer for kids

NCT ID NCT02928991

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study tests a fludarabine-based drug regimen to prepare children with bone marrow failure syndromes for a bone marrow transplant from a matched sibling donor. The goal is to help the donor cells successfully take root while reducing serious side effects. The study includes 25 children up to age 22 with acquired aplastic anemia or inherited bone marrow failure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fludarabine, cyclophosphamide, and thymoglobulin (conditioning drugs) followed by bone marrow transplant
What this could lead to
If successful, this approach could improve donor cell engraftment and reduce transplant-related complications for children with bone marrow failure.
What could go wrong
This is a very early pilot study with only 25 participants, so results may not apply broadly. Risks include graft failure, infection, and transplant-related mortality.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Apr 2015

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Up to 22 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patients 0-22 years with acquired aplastic anemia or a diagnosed inherited bone marrow failure syndrome, and a fully Human leukocyte antigen (HLA)-matched (10/10) related donor. Inclusion Criteria: Patient: 1. Ages 0-22 years at time of enrollment 2. Diseases: * Patients with severe or very severe acquired AA, defined by: * Bone marrow biopsy demonstrating cellularity of \<25% (at least 2 weeks from last dose of G-CSF), in addition to 2 of the following: absolute neutrophil count (ANC) \<500/µL, platelets \< 20,000/µL and absolute reticulocytes \<40,000/µL * Negative evaluation for inherited bone marrow failure conditions and negative evaluation for dysplasia or cytogenetic abnormalities associated with myelodysplastic syndromes * Patients with concurrent paroxysmal nocturnal hemoglobinuria (PNH) clones are eligible, as long as they meet criteria for severe or very severe aplastic anemia as defined above * Patients with clinically diagnosed and/or genetically proven iBMF syndromes, resulting in chronic red blood cell or platelet-transfusion dependence and/or an absolute neutrophil count \<500/µL. These disorders include, but are not limited to: * Fanconi Anemia * Dyskeratosis Congenita * Severe Congenital Neutropenia * Diamond-Blackfan Anemia * Congenital Dyserythropoietic/Sideroblastic Anemias * Congenital Amegakaryocytic Thrombocytopenia * Shwachman-Diamond Syndrome 3. Lansky or Karnofsky performance \>60 4. HLA matched related donor available. 5. No active untreated infection 6. Females of childbearing potential must have negative pregnancy test. Organ Function: * Serum creatinine \<1.5xupper limit of normal for age Hepatic: Transaminases \<5x normal * Cardiac shortening fraction \>27% * Bilirubin \<2.5x normal (unless elevation due to Gilberts disease). Donor Selection Criteria: * Donor selection will comply with U.S. Food and Drug Administration's Code of Federal Regulations * Fully HLA-matched related donor. * Donor must be at least 6 months of age * Donor suitable for bone marrow collection and meets eligibility for donation, including fulfilling infectious disease criteria as per SOP, including HIV, Hepatitis B, Hepatitis C Polymerase chain reaction (PCR) negative. * If subject has confirmed iBMF syndrome, donor must be evaluated for this disorder and testing must be negative * Children's Hospital of Philadelphia (CHOP) bone marrow transplant (BMT) procedures apply for determining donor eligibility, including donor screening and testing for relevant communicable disease agents and diseases. * Donor evaluation and collection procedure as per CHOP Standard Operating Procedures (SOP) Exclusion Criteria: * Uncontrolled bacterial, viral or fungal infections * HLA matched related donor unable to donate bone marrow. * No eligible fully HLA-matched related donor * Pregnant females * Patients with a clinical diagnosis of Myelodysplastic syndrome (MDS) defined by combination of bone marrow dysplasia and classic cytogenetic lesion (Monosomy 7, Trisomy 8 eg.), with or without excess blasts. * Patients with PNH without underlying bone marrow aplasia

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acquired aplastic anemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Children's Hospital of Philadelphia

    Philadelphia, Pennsylvania, 19104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.